Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
Target Audience
BCPPs desiring an evidence-based, in-depth review of contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who are auditory and visual learners and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Complete the pre-test before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (76%).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information




View biographical information
Learning Objectives
- Assess the evidence for treatment options in the management of borderline personality disorder.
- Apply strategies to sustain engagement of patients with personality disorders in treatment.
- Design a rational treatment plan for patients with borderline personality disorder.
- Distinguish between cannabis, hemp, FDA-approved cannabinoids, and synthetic cannabinoids.
- Evaluate the role of cannabis and/or cannabidiol in the treatment of anxiety disorders.
- Assess the safety of cannabis and/or cannabidiol when used for the treatment of anxiety disorders.
- Provide rationale for implementation of a psychiatric pharmacist led psychotropic stewardship program for antipsychotics.
- Assess possible barriers to implementing a psychotropic stewardship program for antipsychotics.
- Measure the effectiveness of a psychotropic stewardship program for antipsychotics.
- Identify factors that contribute to ambivalence to mental health treatment, medication non-adherence, and misalignment between patient and provider goals.
- Compare interventions that address mental health treatment ambivalence and/or medication adherence.
- Recommend strategies to address ambivalence to mental health treatment and non-adherence based on patient-specific factors.
- Assess the impact of pharmacogenomic testing on patient outcomes in psychiatry.
- Incorporate health literacy considerations in education to patients about mental health pharmacogenomic testing results.
- Apply pharmacogenomic results to psychiatric treatment decisions in comprehensive medication management.
Continuing Education Credit and Disclosures
Activity Dates: 04/07/2024 - 10/09/2024
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-24-015-H01-P (Application), 0284-0000-24-016-H01-P (Application), 0284-0000-24-020-H04-P (Application), 0284-0000-24-022-H99-P (Application), 0284-0000-24-024-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2024 Recertification Editorial Board
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: There is no FDA approved pharmacological treatment of Borderline Personality Disorder. All pharmacology discussion will be off-label. Generic terminology will be used whenever possible. Discussion of medication class (rather than mentioning an individual medication) will also be used when appropriate. This presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabis, Cannabidiol (Epidiolex). This presentation will include brand names for some products to reduce confusion. My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Pharmacogenetic test results that are not mentioned in product labeling
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.